CryoCath Technologies (CYT.TO) Buy, Sell or…

CryoCath Technologies (CYT.TO)

0.00

-0.00 (0.00%)

0 watching

TOP PICK

Treats atrial fibrillation (irregular heartbeat). This is a large coming market in cardiac area that is unsolved. The clinical trials they are doing in the US and Europe are indicating that the doctors are really adopting the product. Will probably be the leading therapy in this area. Expecting a takeout, especially if they get FDA approval.

COMMENT

Has some experts telling him he should be looking at this again.

HOLD

As a medical device company its got its risks. The market they are in is not fully developed, so they need to clear the FDA hurdles, develop a market and hit their milestones. Arctic Circler(R) should be a very big piece of that. Expects to have some very good news in 05/06 on this.

DON'T BUY

Just did a financing and the stock can't seem to get beyond the financing price. Unfortunately had to raise cash to get to the next level. Likes the product and the management team. Longer term, it's a good keeper, but doesn't expect a whole lot in the short term. Their US revenues have to ramp up before the market gets excited. Selling his position.

HOLD

Recently did a financing which is typical for a lot of biotech companies. Their research is very interesting. Trying to increase their marketing internationally.

WEAK BUY

Using freezing instead of heat to treat injuries to the heart will be the big driver next year. Good technology that is being accepted. Long term should be good, but short term would be concerned about general market risk.

BUY

Well managed and well financed. Takeover is a possibility.

TRADE

The market is looking for more sales from this company.

HOLD

The value for stock will increase to 8 dollars. Therefore, hold the stocks.

WAIT

Have a great noninvasive product to deal with heart problems. Have a new products in the pipeline. Good potential, but may be fully valued.

BUY

Have a better product for surgeons to cure ablation of the heart. Starting to ramp up with approval in Europe and the US. Next quarter is important as you want to see the hockey stick ramp continue.

BUY

Likes both the product and the space.

BUY

Making substantial progress. The procedure they do takes less time and it had 100% success rate. Starting to see surgeons adopt this. The company will ultimately be sold.

BUY

In a very large and growing market. A technology that is getting more and more accepted. Expecting very large revenue growth out of them this year. New products coming out in the third quarter. Could eventually be a takeover target.

DON'T BUY

Medical device companies are a bit of a minefield because big boys like Abbott, Baxter, Johnson & Johnson control the purchasing through a hospital. Interesting technology. Using a lot of cash. Wait to see their numbers. A high risk situation.

Showing 1 to 15 of 23 entries

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

CryoCath Technologies (CYT.TO) Frequently Asked Questions

What is CryoCath Technologies stock symbol?

CryoCath Technologies is a OTC stock, trading under the symbol CYT.TO (previously CYT-T on Stockchase) on the undefined (undefined). It is usually referred to as or CYT.TO

Is CryoCath Technologies a buy or a sell?

In the last year, no analyst issued a Buy, Sell, or Hold rating on CYT.TO (previously CYT-T on Stockchase) on Stockchase. Read the latest expert commentary for CryoCath Technologies.

Is CryoCath Technologies a good investment or a top pick?

CryoCath Technologies was recommended as a Top Pick by Andrew McCreath on 2004-04-20. Read the latest stock experts ratings for CryoCath Technologies.

Why is CryoCath Technologies stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for CryoCath Technologies.

Is CryoCath Technologies worth watching?

CryoCath Technologies is covered by Stockchase experts and is worth watching.

Most Recent Experts

Jim Cramer - Mad Money

CNBC

Richard Orrell

RN Croft Financial Group

Stockchase Insights

5i Research

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Stan Wong

Private Wealth Management, ScotiaMcleod

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

CryoCath Technologies (CYT.TO)